The Italian Higher Institute of Health (ISS) published this Sunday a preclinical study on a vaccine against coronavirus based on a protein that, unlike the “spike”, is common to all variants and generates “an effective response”.
The results of the study, based on research in animals with which the possibilities of a drug being useful are assessed, have been published in the journal viruses.
The experiment has demonstrated an innovative pathway that generates an “effective and long-lasting” immune response in mice infected with Sars-CoV-2, reads a statement from the ISS.
The method is based on a new strategy that uses the N protein of the virus, which, unlike the well-known “Spike” or spike, which forms the crown, shows practically no mutation in the variants that have emerged to date.
The new mechanism is based on the “engineering” of nanoparticles generated naturally by muscle cells and, according to the ISS, could exceed the limits of current vaccines in terms of antibody expiration and loss of efficacy.
And it is that the researchers have shown that, when these nanoparticles are loaded with the N protein of Sars-CoV-2, an immune reaction can be generated in rodents capable of protecting them from very high viral loads.
The ISS has already scheduled additional studies to clarify points such as the safety of a vaccine or its tolerance, which will be “essential” to lay the foundation for future clinical studies in humans and confirm the efficacy of this discovery. (I)
Source: Eluniverso
Paul is a talented author and journalist with a passion for entertainment and general news. He currently works as a writer at the 247 News Agency, where he has established herself as a respected voice in the industry.
